GLY-200 / Glyscend  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GLY-200 / Glyscend
ACTRN12624000097549: GLY-200 for Duodenal Exclusion (GLYDE Study): Effects of GLY-200 in healthy humans and people with uncomplicated type 2 diabetes.

Not yet recruiting
2
32
 
The University of Adelaide, Glyscend Therapeutics
Type 2 diabetes, Obesity
 
 
NCT05478525: A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

Completed
2
52
US
GLY-200, Placebo
Glyscend, Inc.
Type 2 Diabetes
03/23
03/23
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Active, not recruiting
2
75
US
GLY-200, Placebo
Glyscend, Inc.
Obesity
12/24
12/24

Download Options